Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
Phase 1
Completed
- Conditions
- Similarity of Pharmacokinetics and Safety
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05323981
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT04514419
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection
Phase 1
- Conditions
- Similarity of Pharmacokinetics and Safety
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04361812
- Locations
- 🇨🇳
Anhui Peng, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath